Segment and Geographical Data (Schedule of Segment Reporting Information by Business Segment) (Details) (USD $)	3 Months Ended											12 Months Ended
	Sep. 27, 2013		Jun. 28, 2013		Mar. 29, 2013	Dec. 28, 2012	Sep. 28, 2012		Jun. 29, 2012	Mar. 30, 2012	Dec. 30, 2011	Sep. 27, 2013		Sep. 28, 2012		Sep. 30, 2011
Segment Reporting Information [Line Items]
Net sales	$ 545,200,000		$ 570,000,000	[1]	$ 585,300,000	$ 504,000,000	$ 513,100,000		$ 516,300,000	$ 523,100,000	$ 503,700,000	$ 2,204,500,000		$ 2,056,200,000		$ 2,021,800,000
Operating income (loss)												144,800,000		235,200,000		240,700,000
Intangible asset amortization												(35,400,000)		(27,300,000)		(27,000,000)
Restructuring and related charges, net												(35,800,000)		(19,200,000)		(10,000,000)
Separation costs												(74,200,000)		(25,500,000)		(2,900,000)
Assets	3,556,600,000						2,898,900,000					3,556,600,000		2,898,900,000
Depreciation and amortization												139,600,000		130,900,000		119,800,000
Restructuring and related costs, accelerated depreciation												2,600,000		8,000,000		1,600,000
Specialty Pharmaceuticals
Segment Reporting Information [Line Items]
Restructuring and related charges, net												(16,400,000)		(11,300,000)		(6,500,000)
Global Medical Imaging
Segment Reporting Information [Line Items]
Restructuring and related charges, net												(16,400,000)		(7,900,000)		(3,800,000)
Operating Segments
Segment Reporting Information [Line Items]
Net sales												2,153,300,000	[2]	2,002,000,000	[2]	1,969,400,000	[2]
Operating income (loss)												424,000,000		377,100,000		353,900,000
Operating Segments | Specialty Pharmaceuticals
Segment Reporting Information [Line Items]
Net sales												1,217,600,000		1,005,200,000		909,400,000
Operating income (loss)												311,700,000		162,800,000		121,500,000
Assets	1,666,600,000						1,571,600,000					1,666,600,000		1,571,600,000
Depreciation and amortization												97,600,000	[3]	88,700,000	[3]	77,500,000	[3]
Operating Segments | Global Medical Imaging
Segment Reporting Information [Line Items]
Net sales												935,700,000		996,800,000		1,060,000,000
Operating income (loss)												112,300,000		214,300,000		232,400,000
Assets	1,158,600,000						1,085,700,000					1,158,600,000		1,085,700,000
Depreciation and amortization												42,000,000	[3]	42,200,000	[3]	42,300,000	[3]
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Net sales												51,200,000	[4]	54,200,000	[4]	52,400,000	[4]
Corporate and allocated expenses												(133,800,000)	[5]	(69,900,000)	[5]	(73,300,000)	[5]
Intangible asset amortization												(35,400,000)		(27,300,000)		(27,000,000)
Restructuring and related charges, net												(35,800,000)	[6]	(19,200,000)	[6]	(10,000,000)	[6]
Separation costs												(74,200,000)		(25,500,000)		(2,900,000)
Assets	731,400,000	[7]					241,600,000	[7]				731,400,000	[7]	241,600,000	[7]
Intersegment Eliminations
Segment Reporting Information [Line Items]
Net sales												$ 0		$ 0		$ 0

[1] Operations in the third quarter of fiscal 2013 were impacted by the Separation.

[2] Amounts represent sales to external customers. There were no intersegment sales.

[3] Depreciation for certain shared facilities is allocated based on occupancy percentage.

[4] Represents products that were sold to Covidien, which is discussed in Note 16.

[5] Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.

[6] Includes restructuring-related accelerated depreciation of $2.6 million, $8.0 million and $1.6 million for fiscal 2013, 2012 and 2011, respectively.

[7] Consists of assets used in managing the Company's total business and not allocated to any one segment.